gutflix
GI learning, personalised

Summary

USE OF FK-ADA BIOSIMILAR (MSB 11022) IN CONTEXT OF BIOLOGIC SWITCH IN INFLAMMATORY BOWEL DISEASES: BASELINE DATA OF THE REAL WORLD IDEA STUDY

Joelle Monnet

UEG Week Vienna 2024 Poster

IBD

October 13, 2024

The IDEA study is an ongoing real-world observational study examining treatment persistence in 138 IBD patients switched to FK-ada adalimumab biosimilar from originator or other biosimilars, with baseline characteristics showing most patients in clinical remission or mild to moderate disease activity.

KEY POINTS

- 138 adult IBD patients (113 Crohn's disease, 25 ulcerative colitis) were recruited across 18 centres, with median disease duration of 11.4 years and 90% having secondary or university education
- At baseline, 97.3% of CD patients and 88.0% of UC patients were in clinical remission or had mild to moderate disease activity, with median fecal calprotectin of 73.0 mcg/mg
- 54% of patients switched from adalimumab originator and 43% from another adalimumab biosimilar, with administrative or economic reasons accounting for 88% of switches from originator and 65% from biosimilar
- The study aims to identify predictive factors of treatment persistence at 12 months after switch to FK-ada, with 52-week follow-up data collection ongoing
- This material is most relevant for gastroenterologists managing IBD patients and those involved in biosimilar switching decisions

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/400ffdba-9111-11ef-8ab2-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.